# Amneal Pharmaceuticals account plan

> Amneal Pharmaceuticals makes complex generics, biosimilars and specialty drugs, with $3,018.8 million of 2025 revenue and over 8,500 employees.

## At a glance

Amneal Pharmaceuticals (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, develops, manufactures and distributes generic, injectable, biosimilar and branded medicines, operating principally in the U.S., India and Ireland. It has about 300 complex generic, specialty and biosimilar medicines and delivers more than 160 million prescriptions a year, mainly in the United States. FY2025 net revenue was $3,018.8 million (+8.0%), operating income $394.1 million and net income $127.9 million. It had over 8,500 employees at end-2025, excluding about 200 at AvKARE. Co-founders Chirag Patel and Chintu Patel are Co-CEOs; four wholesalers and pharmacies (Cencora, McKesson, Cardinal Health, CVS Health) were about 71% of revenue.

## Business units

- **Affordable Medicines** (about 58% of FY2025 revenue ($1,745.5 million)): Retail generics, sterile injectables, inhalation products, transdermal patches and biosimilars, with over 280 product families, 61 pending ANDAs and 43 more in development. 2025 revenue grew 3.6%; Q3 2026 revenue rose 18.7% to $547.1 million on biosimilars, women's health patches and new launches. Kashiv BioSciences is reported here since August 2026.
- **Specialty** (about 18% of FY2025 revenue ($528.5 million)): Branded central nervous system and endocrine drugs: CREXONT and RYTARY for Parkinson's disease, UNITHROID for hypothyroidism and the BREKIYA autoinjector for migraine. 2025 revenue grew 18.6% and Q3 2026 revenue rose 20.0% to $150.3 million, offsetting the expected RYTARY decline.
- **AvKARE** (about 25% of FY2025 revenue ($744.7 million)): Distribution and re-packaging of pharmaceuticals for the U.S. Department of Defense, Veterans Affairs, retail and institutional customers; Amneal holds 65.1%. 2025 revenue grew 12.3% on the government label channel, while Q3 2026 revenue fell 16.7% after a non-recurring cardiovascular launch in the prior year.

## Strategic priorities

- **Biosimilars as main growth driver**: With Kashiv closed, Amneal has end-to-end biosimilar capabilities and over 20 biosimilar programs; biosimilars are expected to drive most growth toward a 2030 revenue target of $4.3-$4.5 billion.
- **Complex generics and injectables**: Launches include women's health transdermal patches, lanreotide (30%-40% share targeted), romidepsin and iohexol, with a next wave of sterile injectables and bag products in 2027-2029 and five more inhalation approvals targeted over three years.
- **Grow Specialty brands**: CREXONT adds around 400 new prescribers a month and Amneal aims to make it first-line therapy; BREKIYA is ahead of expectations; M&A focus turns to CNS and oncology assets.
- **U.S. manufacturing expansion**: Capacity is being added for women's health patches, U.S. sterile injectables by 2028, two GLP-1 facilities for the Pfizer collaboration and biosimilar drug substance, from about 26,000 liters to about 75,000 liters by 2028.
- **Deleveraging**: Net leverage was 3.0x at Q3 2026, expected at 3.6x at year-end and below 3x by 2028.

## Latest results

In Q3 2026 (quarter to September 30, 2026) net revenue rose 10.0% to $862.7 million, with Affordable Medicines up 18.7% and Specialty up 20.0%, while AvKARE fell 16.7%. Operating income rose 35.6% to $95.4 million, but the GAAP net loss attributable to Amneal was $22 million because of acquisition costs and a higher tax provision. Adjusted EBITDA rose 30% to $207 million. FY2026 guidance was raised to net revenue of $3.15-$3.25 billion and adjusted EBITDA of $800-$815 million, while operating cash flow guidance was cut to $325-$375 million on higher inventory.

## Investments and deals

- **Kashiv BioSciences acquisition**: Closed August 10, 2026 for a preliminary $1.3 billion: $375.0 million cash and 28.9 million shares, up to $350.0 million of milestones and royalties; $400-$500 million of financial benefits are expected.
- **Capital expenditure**: 2026 capex guidance was raised from about $110 million to about $150 million for women's health demand and U.S. injectable expansion.
- **GLP-1 facilities for Pfizer**: Amneal is building API and fill-finish facilities in India, with construction completing late 2028 to 2029; Metsera, acquired by Pfizer, funds up to $100 million.
- **Injectables partnerships**: A 15-year ApiJect collaboration installs blow-fill-seal equipment at Brookhaven, New York, which was selected for the FDA PreCheck pilot programme.
- **Financing**: An extra $350.0 million was added to the Term Loan Due 2032 for Kashiv; total indebtedness was $2.7 billion at end-2025.

## Challenges and risks

- **Generic price erosion and RYTARY generics**: Generic competition brings volume and price erosion, and multiple RYTARY generics are expected.
- **Customer concentration**: Four customers accounted for about 71% of 2025 revenue.
- **Tariffs on pharmaceutical imports**: A preliminary proposal keeps generic imports tariff-free through July 31, 2028, then 100% for one year and 200% after, which could raise costs of products made outside the U.S., including India.
- **Leverage and integration risk**: Kashiv raised indebtedness and exposure to biosimilar development and launch risks; net leverage is expected at 3.6x at end-2026.
- **Operational and legal events**: July 2026 flooding at an Indian plant cost $5.4 million; the nationwide opioid settlement and an $8.0 million charge for government investigations weigh on results.

## What leadership says

> "Amneal now has the end-to-end capabilities to succeed in biosimilars" — Chirag Patel, Co-Founder, President and Co-CEO, Q3 2026 earnings call, November 3, 2026

> "to become America's number one affordable medicines company and a leading provider of essential medicines globally" — Chirag Patel, Co-Founder, President and Co-CEO, Q3 2026 earnings call, November 3, 2026

> "Amneal is in the midst of the most transformative period in our company's history." — Chirag Patel, Co-Founder, President and Co-CEO, Q2 2026 earnings call, July 30, 2026

> "Complex generics build this company, and we are not slowing down." — Chintu Patel, Co-Founder and Co-CEO, Q3 2026 earnings call, November 3, 2026


## Where a supplier can help

- **Biologics manufacturing capacity**: Tied to the biosimilars priority and the drug substance expansion: bioprocess equipment, single-use systems and CDMO support for scaling capacity by 2028.
- **Sterile injectable and patch production**: Tied to the U.S. manufacturing expansion: fill-finish, packaging and automation suppliers fit new sterile and transdermal capacity.
- **Supply chain and tariff planning**: Tied to the tariff challenge: sourcing, trade compliance and API dual-sourcing services for products made in India.
- **Integration and digital operations**: Tied to the Kashiv integration and the digitization of 20 facilities: ERP, quality systems and AI tools for manufacturing efficiency.
- **Specialty commercial support**: Tied to the Specialty priority: prescriber targeting, market access and patient programmes for CREXONT and BREKIYA.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000011/amrx-20251231.htm)

Annual report · 2026-02-27

- Amneal Pharmaceuticals (Nasdaq: AMRX, HQ Bridgewater, New Jersey) is a diversified, global biopharmaceutical company developing, manufacturing and distributing essential medicines; it operates principally in the U.S., India and Ireland, with three segments: Affordable Medicines, Specialty and AvKARE.
- FY2025 net revenue was $3,018.8 million, up 8.0% from $2,794.0 million; gross margin rose to 36.9% (from 36.5%), operating income rose 58.1% to $394.1 million and the company swung to net income of $127.9 million from a $73.9 million loss in 2024.
- Affordable Medicines (generics, injectables, biosimilars) is the largest segment at $1,745.5 million (+3.6%), with over 280 product families, 61 pending ANDAs and 43 more products in development, 95% of them non-oral solids; new launches added $122.6 million.
- Specialty (branded CNS and endocrine drugs: CREXONT, RYTARY, UNITHROID, Brekiya) grew 18.6% to $528.5 million; CREXONT added $58.1 million and its U.S. insurance coverage went from about 30% to over 50% of covered lives; the Brekiya autoinjector for migraine launched in October 2025.
- AvKARE (distribution to the U.S. Department of Defense, Veterans Affairs, retail and institutional customers) grew 12.3% to $744.7 million, with gross margin up to 19.7% from 15.6% on the government label channel.
- Five biosimilars now commercial in the U.S. after the December 2025 FDA approval of two denosumab biosimilars (Boncresa and Oziltus); the company sees biosimilars as a key long-term growth driver. First inhalation approvals (generic ProAir HFA, tentative generic QVAR) came from its Ireland plant.
- Over 8,500 employees (excluding about 200 at AvKARE), nearly 2,500 in the U.S. and over 6,000 outside, mainly India and Ireland; the four largest customers (Cencora, McKesson, Cardinal Health, CVS Health) were about 71% of revenue.
- Balance sheet: $2.7 billion of total indebtedness (Term Loan Due 2032 and $600.0 million Senior Notes Due 2032), refinanced in August 2025 and repriced by 50 basis points in February 2026; about $110.0 million of capex planned for 2026.
- Key risks: generic price erosion and competition, customer concentration, U.S. tariffs and the Section 232 pharmaceutical investigation, RYTARY generic erosion, opioid litigation (nationwide settlement effective January 29, 2026) and high leverage. Co-founders Chirag Patel and Chintu Patel are Co-CEOs; Paul M. Meister chairs the board.

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000040/amrx-20260930.htm)

Interim report · 2026-11-09

- Q3 2026 (quarter to September 30, 2026) net revenue was $862.7 million, up 10.0%; gross margin 38.7% (34.9%); operating income $95.4 million (+35.6%); net income $12.3 million (Q3 2025: $18.1 million).
- Affordable Medicines revenue $547.1 million (+18.7%): new launches added $53.7 million, biosimilar revenue rose $60.7 million and women's health medicines grew; segment gross margin fell to 35.6% from 39.1%.
- Specialty revenue $150.3 million (+20.0%) on CREXONT (+$14.8 million), BREKIYA autoinjector (+$6.2 million) and UNITHROID (+$5.6 million), offsetting the expected RYTARY decline; segment gross margin 69.2%.
- AvKARE revenue $165.3 million (-16.7%) because a non-recurring cardiovascular product launch boosted the second half of 2025.
- Kashiv BioSciences acquisition closed August 10, 2026 for a preliminary $1.3 billion: $375.0 million cash and 28.9 million Class A shares at closing, up to $350.0 million of milestone payments and 25% royalties above gross profit hurdles; $1,003.0 million of intangibles recognised; all goodwill in Affordable Medicines.
- Financing: an extra $350.0 million under the Term Loan Due 2032 and $180.0 million drawn on the revolver at September 30, 2026; acquisition-related costs $19.0 million in the quarter, $31.7 million year to date.
- Nine months: revenue $2,381.4 million (+8.0%), gross margin 41.5% (37.0%), net income $159.9 million (+104.1%).
- Events and risks: July 2026 flooding at an Indian plant ($5.4 million of charges); Section 232 tariffs of up to 100% on some branded drugs (generics and biosimilars exempt) and a proposed generic tariff from August 2028; an $8.0 million charge for government investigations.

### [Amneal Reports Third Quarter 2026 Financial Results (press release)](https://www.sec.gov/Archives/edgar/data/1723128/000172312826000035/amrx-q32026ex991.htm)

Interim report · 2026-11-03

- Q3 2026 net revenue $863 million (+10%); GAAP net loss attributable to Amneal $22 million, diluted loss per share $(0.06), due to acquisition and integration costs and a higher tax provision.
- Adjusted EBITDA $207 million (+30%); adjusted diluted EPS $0.26 (+53% from $0.17).
- Affordable Medicines +19% on biosimilars, women's health patches and new launches; Specialty +20% on CREXONT, BREKIYA autoinjector and UNITHROID; AvKARE -17% as expected.
- FY2026 guidance raised: net revenue $3.15-$3.25 billion (prior $3.10-$3.20 billion), adjusted EBITDA $800-$815 million (prior $750-$780 million), adjusted diluted EPS $1.04-$1.08 (prior $0.96-$1.06).
- Operating cash flow guidance cut to $325-$375 million (prior $350-$400 million) on higher inventory in growth areas; capex ~$150 million; discrete items include ~$36 million of opioid settlement costs and ~$40 million of Kashiv costs.
- Co-CEOs Chirag and Chintu Patel cite 2027 catalysts: women's health patches, biosimilars, injectables such as lanreotide, CREXONT and BREKIYA autoinjector, and say the Kashiv integration "is proceeding well".
- Amneal has about 300 complex generic, specialty and biosimilar medicines and more than 160 million prescriptions a year, mainly in the U.S.

### [Amneal (AMRX) Q3 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/11/03/amneal-amrx-q3-2026-earnings-call-transcript/)

Executive talk · Chirag Patel, Co-Founder, President and Co-Chief Executive Officer · 2026-11-03

- Chirag Patel: 2026 is Amneal's "seventh consecutive year of top and bottom line growth"; Q3 revenue $863 million (+10%), adjusted EBITDA $207 million (+30%), adjusted EPS $0.26 (+53%).
- Kashiv closed in Q3, giving end-to-end biosimilar capabilities; about $234 billion of U.S. biologic sales lose exclusivity over the next decade; biosimilars are expected to drive most of the growth toward the 2030 target of $4.3-$4.5 billion revenue.
- Complex generics: women's health transdermal patches, lanreotide (launched late September, about $7 million in Q3, 30%-40% share targeted), romidepsin, iohexol; five more inhalation approvals targeted over three years; a next wave of sterile injectable and bag launches in 2027-2029.
- Specialty: CREXONT adds around 400 new prescribers a month; BREKIYA has doubled internal expectations and could nearly double again next year (Joe Renda).
- FY2026 guidance raised to revenue $3.15-$3.25 billion and adjusted EBITDA $800-$815 million; operating cash flow lowered to $325-$375 million on inventory build; net leverage 3.0x, below 3x expected by 2028.
- XOLAIR biosimilar launch expected late in the second half of 2027, Amneal second after Celltrion; denosumab presentations mid-2027; Pfizer GLP-1 facilities to complete late 2028 to 2029.
- Kashiv benefits of $400-$500 million targeted: Amneal now keeps 100% of lanreotide profits and secured $60 million of New Jersey tax credits.
- Stated goal: "to become America's number one affordable medicines company and a leading provider of essential medicines globally".

### [Amneal (AMRX) Q2 2026 Earnings Call Transcript](https://www.fool.com/earnings/call-transcripts/2026/07/30/amneal-amrx-q2-2026-earnings-call-transcript/)

Executive talk · Chirag Patel, Co-Founder, President and Co-Chief Executive Officer · 2026-07-30

- Q2 2026 revenue $796 million (+10%), adjusted EBITDA $206 million (+12%), adjusted EPS $0.30 (+20%); Chirag Patel: Amneal is "in the midst of the most transformative period in our company's history."
- FY2026 guidance raised to revenue $3.1-$3.2 billion, adjusted EBITDA $750-$780 million (including an estimated $20 million hit from the Gujarat flood) and adjusted EPS $0.96-$1.06; capex raised from about $110 million to about $150 million.
- Kashiv (pending at the time) creates a fully integrated biosimilar platform: over 20 biosimilar programs, drug substance capacity from about 26,000 liters at end-2026 to about 75,000 liters by 2028; $400-$500 million of expected financial benefits; net leverage below 3x by 2028.
- 118 biologics expected to lose U.S. exclusivity over the next decade; portfolio about 75% lower-competition and 25% larger opportunities; targets XOLAIR, ORENCIA, CIMZIA and Nplate biosimilars.
- Affordable Medicines could add "$1 billion to $2 billion of new revenue from now to 2030"; estrogen patch capacity to triple by next year; 12 to 15 complex ANDA filings planned this year.
- Brookhaven, New York selected as one of seven companies in the FDA PreCheck pilot programme; term loan repricing saves $12 million a year in interest.
- Specialty: 80% of CREXONT scripts come from general neurologists; a new Phase IV study begins in Q4; Amneal will look at CNS and oncology assets for acquisition.

## Questions about Amneal Pharmaceuticals

### What does Amneal Pharmaceuticals do?

Amneal develops, manufactures and distributes complex generics, injectables, biosimilars and branded CNS and endocrine drugs, and distributes medicines to U.S. government and institutional customers through AvKARE.

### What is Amneal's revenue?

FY2025 net revenue was $3,018.8 million, up 8.0%. FY2026 guidance is $3.15-$3.25 billion, and the 2030 target is $4.3-$4.5 billion.

### How many employees does Amneal have?

Over 8,500 employees at end-2025, excluding about 200 at AvKARE: nearly 2,500 in the U.S. and over 6,000 outside, mainly in India and Ireland.

### Who leads Amneal?

Co-founders Chirag Patel (President and Co-CEO) and Chintu Patel (Co-CEO) lead the company; Anastasios Konidaris is CFO and Paul M. Meister is Chairman.

### What is Amneal's strategy?

Amneal focuses on biosimilars, complex generics and injectables, growth of its Specialty brands and U.S. manufacturing expansion, aiming to become America's number one affordable medicines company.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
